Imatinib and pegylated IFN-alfa2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33150373" target="_blank" >RIV/61989592:15110/14:33150373 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1111/ejh.12258" target="_blank" >http://dx.doi.org/10.1111/ejh.12258</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.12258" target="_blank" >10.1111/ejh.12258</a>

Result language
angličtina
Original language name
Imatinib and pegylated IFN-alfa2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Original language description
OBJECTIVES: Previous studies indicate that 40-50% of patients with chronic myeloid leukemia in prolonged complete molecular remission may discontinue imatinib therapy without imminent relapse. The combination of pegylated interferon-alpha (Peg-IFN-alfa2b) and imatinib may increase the rate of successful discontinuation. METHODS: In this pilot study, we prospectively stopped imatinib from patients (n = 12) who had achieved major molecular response (MMR) after ?12 months of treatment with either imatinibor imatinib+Peg-IFN-alfa2b. Molecular monitoring was carried out monthly for BCR-ABL1. In addition, analyses of lymphocyte immunophenotype, function, and plasma cytokines were performed. RESULTS: In the monotherapy group, 5/6 patients lost MMR within 4 months. One patient remains to date in MR(4.0) 61 months after discontinuation. In the combination therapy group, 2/6 patients relapsed within 4 months while still receiving Peg-IFN-alfa2b. Four of six patients were able to discontinue bot
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT12218" target="_blank" >NT12218: Personalized treatment of chronic myeloproliferative disorders and myelodysplastic syndrome - a cellular metabolomics study.</a><br>
Continuities
S - Specificky vyzkum na vysokych skolach

Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)